HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

apratoxin S10

derivative of apratoxin

Also Known As:

apra S10

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Depsipeptides: 297
      - apratoxin S10: 3
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Depsipeptides: 297
      - apratoxin S10: 3

Experts

1.	Cai, Weijing: 3 articles (01/2019 - 10/2017)
2.	Chen, Qi-Yin: 3 articles (01/2019 - 10/2017)
3.	Luesch, Hendrik: 3 articles (01/2019 - 10/2017)
4.	Dang, Long H: 2 articles (12/2017 - 10/2017)
5.	Derendorf, Hartmut: 1 article (01/2019)
6.	Gerber, Michael H: 1 article (01/2019)
7.	Ratnayake, Ranjala: 1 article (01/2019)
8.	Trevino, Jose G: 1 article (01/2019)
9.	Yu, Yichao: 1 article (01/2019)

Related Diseases

1.	Neoplasms (Cancer) 12/14/2017 - "Correction to "Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors"." 10/12/2017 - "We showed that apratoxin S10 potently inhibits both angiogenesis in vitro and growth of cancer cells from vascularized tumors. " 10/12/2017 - "Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors." 10/12/2017 - "Apratoxin S10 down-regulated vascular endothelial growth factor receptor 2 (VEGFR2) on endothelial cells and blocked the secretion of VEGF-A and IL-6 from cancer cells. "
2.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2019 - "Apra S10 showed promising antitumor effect in this pancreatic cancer model and this effect was mediated through anti-proliferation properties." 01/01/2019 - "Apra S10 also inhibited a number of cytokines secreted by stromal cells, suggesting that Apra S10 not only inhibited pancreatic cancer cell secretion, but also reduced the level of factors secreted by other cell types active within the tumor microenvironment. " 01/01/2019 - "Here, we developed apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent which potently inhibited the growth of both established and patient-derived primary pancreatic cancer cells. " 01/01/2019 - "Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model."

Related Drugs and Biologics

1.	apratoxin S10
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
4.	Cytokines
5.	Interleukin-6 (Interleukin 6)